Fund+

Fund+ is a Belgian venture capital firm that focuses on long-term equity investments in innovative life sciences companies. Established in 2015, the firm aims to create both financial returns and a positive societal impact, primarily investing in therapeutics, diagnostics, and medical devices. Fund+ seeks to address unmet medical needs, with a patient-centric approach. The firm typically invests between €5 million and €15 million per project and plays an active role in its portfolio companies, often taking a seat on the board to provide strategic guidance. With over €200 million in assets under management, Fund+ has built a strong track record, investing in 13 high-potential companies, with two notable exits. The firm's portfolio includes companies such as Indigo Diabetes, which is developing a revolutionary invisible glucose monitoring device, and ExeVir Bio, which focuses on antiviral nanobody treatments for global viral threats. Fund+ also supports companies like Novadip Biosciences, which is developing advanced tissue regeneration therapies, and Confo Therapeutics, known for its groundbreaking GPCR-targeted drug discovery platform. Fund+ operates with a long-term vision, aiming to bolster the life sciences ecosystem in Belgium while fostering innovations that improve patient outcomes globally. Its diverse portfolio reflects a commitment to supporting groundbreaking scientific advancements that have the potential to transform healthcare.